Document Detail

Treatment adherence in patients with gout.
MedLine Citation:
PMID:  21724443     Owner:  NLM     Status:  Publisher    
The treatment objectives in gout are to promptly terminate the acute flares and to prevent the long-term complications via chronic pharmacotherapy, usually with urate-lowering drugs, combined with diet and lifestyle changes. Published data indicate that adherence with pharmacotherapy is particularly poor in gout patients. In studies of pharmacy dispensing of gout medications, the percentage of patients with good adherence, defined as purchasing at least 80% of the prescribed amount of medication, ranged from 18 to 44%. In a comparative study showing a 36.8% adherence rate among gout patients, patients with hypertension or type 2 diabetes had considerably higher rates, of 72.3 and 65.4%, respectively. In addition, data are lacking on adherence to recommended dietary and lifestyle changes, whose importance has been emphasized in recent years. Poor adherence has well-documented adverse consequences on the treatment success rate and on disease progression. These data identify treatment adherence in gout as a key target of patient education.
Gérard Reach
Related Documents :
21939403 - Barriers to antiretroviral adherence in hiv-positive patients receiving free medication...
21778893 - Guideline adherence and outcomes in esophageal variceal hemorrhage: comparison of terti...
12070003 - Hla class ii haplotype and quantitation of wt1 rna in japanese patients with paroxysmal...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-7-1
Journal Detail:
Title:  Joint, bone, spine : revue du rhumatisme     Volume:  -     ISSN:  1778-7254     ISO Abbreviation:  -     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-7-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100938016     Medline TA:  Joint Bone Spine     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011. Published by Elsevier SAS.
EA 3412, CRNH-IdF, service d'endocrinologie, diabétologie, maladies métaboliques, hôpital Avicenne, AP-HP, université Paris 13, Bobigny, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Suggestive linkage to chromosome 1q for bone mineral apparent density in Brazilian sister adolescent...
Next Document:  Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, copre...